REYVOW (nda211280)- (EQ 50MG BASE,EQ 100MG BASE,EQ 200MG BASE)

Generic Name	LASMIDITAN SUCCINATE	Innovator	ELI LILLY AND CO
Dosage	EQ 50MG BASE,EQ 100MG BASE,EQ 200MG BASE
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2040-Jul-06	NCE Excl Expiry	2025-Jan-31
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	REYVOW® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	5

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 50MG BASE	**	**	Up	-	-
EQ 100MG BASE	**	**	Up	-	-
EQ 200MG BASE	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of REYVOW